Clinical Trials Browser

Immunotherapy × tislelizumab × Clear all

NCT05223088 2025-03-18

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Immunotherapy

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Immunotherapy